5 Cash-Rich Small Cap Stocks To Invest In

2. Merus N.V. (NASDAQ:MRUS)

Number of Hedge Fund Holders: 31

Merus N.V. (NASDAQ:MRUS) operates as a clinical-stage immuno-oncology company that focuses on developing bispecific antibody therapeutics alongside therapeutics to treat and cure cancer patients.

On January 4, EF Hutton analyst Tony Butler initiated coverage of Merus N.V. (NASDAQ:MRUS) with a Buy rating and $35 price target. According to the analyst, the company’s bispecific anticancer antibodies arising from its Biclonics platform are selected because of the functional ability of the antibody to eradicate tumor cells. To date, four antibodies borne from the Merus platform have elicited anticancer responses in a number of indications.

As of the end of the third quarter, 31 hedge funds tracked by Insider Monkey reported having stakes in Merus N.V. (NASDAQ:MRUS). The total value of these stakes was $346 million. Mark Lampert’s Biotechnology Value Fund / BVF Inc, which had a $69 million stake in Merus N.V. (NASDAQ:MRUS) at the end of September, was the company’s biggest shareholder.

Follow Merus N.v. (NASDAQ:MRUS)